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Introduction: The prevalence of ADHD among patients with substance use disorder (SUD) is substantial. This
study addressed the following research questions: Are early developmental, temperamental and educational
problems overrepresented among SUD patients with ADHD compared to SUD patients without ADHD? Do this
comorbid group receive early help for their ADHD, and are there signs of self-medicating with illicit central
stimulants?
Method:An international,multi-centre cross-sectional studywas carried out involving seven European countries,
with 1205 patients in treatment for SUD. The mean age was 40 years and 27% of the sample was female. All par-
ticipants were interviewed with the Mini International Neuropsychiatric Interview Plus and the Conners' Adult
ADHD Diagnostic Interview for DSM-IV.
Results: SUD patients with ADHD (n=196; 16.3% of the total sample) had a signiﬁcantly slower infant develop-
ment than SUD patients without ADHD (n=1,009; 83.4%), had greater problems controlling their temperament,
and had lower educational attainment. Only 24 (12%) of the current ADHD positive patients had been diagnosed
and treated during childhood and/or adolescence. Finally, SUD patients with ADHD were more likely to havee, Nye Sandviksvei 84, 5032 Bergen, Norway.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
14 A. Skutle et al. / Addictive Behaviors Reports 2 (2015) 13–18central stimulants or cannabis as their primary substance of abuse, whereas alcohol usewasmore likely to be the
primary substance of abuse in SUD patients without ADHD.
Conclusion: The results emphasize the importance of early identiﬁcation of ADHD and targeted interventions in
the health and school system, as well as in the addiction ﬁeld.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Studies in the general population have shown a prevalence of adult
ADHD of 3–5%. However, among persons with a substance use disorder
(SUD) the prevalence rate is signiﬁcantly higher (Kessler et al., 2006). A
meta-analysis of treatment seeking SUD patients reported an overall
prevalence of adult ADHD of 23% (van Emmerik-van Oortmerssen
et al., 2012). However, prevalence rates vary greatly in different studies,
due to the variation in measurement methods and patient characteris-
tics, including age, country and primary substance of abuse. In a recent
international, multi-centre study applying the same assessment
methods in all participants from treatment centres in 10 countries, the
prevalence of adult ADHD in treatment seeking SUD patients still
ranged from 6% to 33% with an average of 14% (van de Glind et al.,
2013), suggesting that health care organization, treatment setting and
patient characteristics play an important role in the attraction of
ADHD patients to addiction treatment centres.
According to the diagnostic criteria for ADHD, the ﬁrst symptoms
need to be already present in early childhood, before 7 years of age in
DSM-IV and before 12 years in DSM-5 (APA, 2013) with evidence of
functional impairment in multiple settings. A recent study showed
that high school students with ADHD were signiﬁcantly more likely to
repeat a grade even after adjusting for all other variables, indicating
the importance of early identiﬁcation of ADHD to help mitigate adverse
educational outcomes (Fried et al., in press). Early difﬁculties known to
be associatedwith ADHDmay be of particular relevance in the develop-
ment of SUD. In a study comparing a group of ADHD-only patients with
a group of patients with SUD and ADHD, the latter group had signiﬁ-
cantly higher rates of comorbid oppositional deﬁant disorder and con-
duct disorder, difﬁcult temperamental traits (obstinacy, bad temper,
impulsive behaviour), maladaptive behaviours at school, familial SUD
history, childhood maltreatment, and severe childhood ADHD symp-
toms (Nogueira et al., 2011).
The present study focuses on ADHD-associated difﬁculties and child-
hood vulnerability among treatment seeking SUD patients with and
without ADHD. The data are obtained from the international
multicentre study on ADHD, presented in detail in a paper by van de
Glind et al. (2013). In this paper, we try to answer the following
questions: (1) to what extent do treatment seeking SUD patients with
adult ADHD, compared to thosewithout adult ADHD, have a delayed in-
fant development, more temperamental problems andmore difﬁculties
at school?; (2) howmany of those treatment seeking SUD patients with
adult ADHD were recognized and treated as such as a child, and which
kind of treatment did they receive?; and (3) what are the main sub-
stances currently used in treatment seeking SUD patients with and
without adult ADHD, and is the use of central stimulants, like amphet-
amine, metamphetamine and cocaine, overrepresented in the group
with adult ADHD, suggesting the presence of self-medication?
2. Method
2.1. Study design and recruitment of patients
A cross-sectional design was applied in a number of treatment cen-
tres from seven European countries: Sweden, Norway, Netherlands,
Switzerland, France, Spain and Hungary (van de Glind et al., 2013).
The project was approved by each country's or institute's related ethicalresearch committee, and the participationwas voluntary. The addiction
centres involved offered inpatient and/or outpatient treatment for var-
ious substance use disorders, and the patients were invited to partici-
pate. Exclusion criteria were substance intoxication, acute psychiatric
crisis such as psychosis or manic episodes, limited literacy or cognitive
impairment, unwillingness to sign informed consent, or other practical
problems. The participating patients gave their written informed con-
sent. The diagnostic stage of the study was preferably performed
while patients were abstinent but exceptions were made based on the
clinician's judgement, since full sustained abstinence as a study require-
ment would have most likely led to high non-participation rates and
limited generalizability. As there is no information on the level of sub-
stance use at the time of interview, there is no information on the per-
centage of abstinent patients versus non-abstinent patients.2.2. Instruments
The Mini International Neuropsychiatric Interview (M.I.N.I.) Plus,
version 5.0.0 (Sheehan et al., 1998) was used to assess DSM-IV sub-
stance use disorders and the primary substances currently used, as
well as other current mental health problems, such as episodes of
mood disorders and antisocial personality disorder.
The Conners' Adult ADHD Diagnostic Interview for DSM-IV
(CAADID; Epstein, Johnson, & Conners, 2001), a semi-structured inter-
view, was used for the diagnosis of adult ADHD. CAADID (Part II) in-
cludes a thorough assessment of the DSM-IV criteria for adult ADHD
including a) number of symptoms, b) age of onset, c) pervasiveness,
d) impairment and e) symptoms that cannot be explained by another
psychiatric disorder. The CAADID has good psychometric properties
and, and Kappa statistics for individual symptomsof inattention and hy-
peractivity–impulsivity were in the fair to good range for current report
and retrospective childhood report (Epstein & Kollin, 2006). The
CAADID is based on DSM-IV criteria, but the diagnostic algorithm was
adapted to make the ﬁndings suitable for DSM-5. The differences be-
tween DSM-IV and DSM-5 in this sample are minimal (van de Glind
et al., 2013). Ideally, the self-report should be supplemented by collater-
al information, but itwas difﬁcult to obtain such information fromchild-
hood, home or school due to the many dissolved families and broken
relationships.
In addition, the CAADID (Part I) deals with the important psycholog-
ical and social difﬁculties in childhood and adolescence associated with
ADHD, including delayed infant development, problems controlling
temper, educational difﬁculties, and indicators of professional help for
ADHD and ADHD-associated problems during childhood and/or adoles-
cence. A problem score was calculated for each problem area based on
the number of afﬁrmative answers in CAADID, indicating problem se-
verity. The following CAADID sections were selected for the study:2.2.1. Delayed infant development
This includes developmental milestones in childhood, such as walk-
ing, talking, and toilet training (4 questions: index range 0–4).2.2.2. Temperamental problems in infancy and early childhood
This includes rage, anxiety, behavioural problems, clumsiness, eating
and sleep problems (13 questions: index range 0–13).
15A. Skutle et al. / Addictive Behaviors Reports 2 (2015) 13–182.2.3. School-related difﬁculties
This includes repeated grades, learning disabilities, extra tuition, ex-
pulsion from school, underachievement in primary school (15 questions:
index range 0–15), and inmiddle/high school (16 questions: index range
0–16).2.2.4. Early diagnosis and professional help
The patients were also asked whether they received a diagnosis of
ADHD as a child, and whether they received any professional help
from a counsellor, psychologist or psychiatrist as a child or adolescent,
and for what kind of difﬁculties. The patients' drug taking history was
also recorded.
In addition, the patient's current substance usewas assessed, includ-
ing use of alcohol, opiates, central stimulants, cannabis and other sub-
stances. Many of the patients in the study were polydrug abusers, but
for the purpose of the current study only the most frequently used
drug was selected for the analysis.2.3. Statistics
Cross tabulation and chi-square statistics were used in relation to
prior diagnosis and treatment. Because of lack of homogeneity of vari-
ance between the two patient groups, non-parametric U-tests for inde-
pendent samples were used for all between group comparisons. For the
non-parametric tests, effect size estimates were based on Z values (r=
Z / √N), indicating the variance explained by the analysed effect. Accord-
ing to Cohen, a small effect is equivalent to 0.1, a moderate effect to 0.3
and a large effect to 0.5 (Cohen, 1992). The number of patients included
in the different analyses varied depending on the degree of completion
of the various parts of CAADID, although theoverall completion ratewas
good. Due to large differences in sample sizes between the two groups,
U-tests were also performed on randomized samples based on 20% of
the SUD patients without adult ADHD and 100% of the SUD patients
with adult ADHD, to make the number of patients similar for the two
groups. All computations were made using the statistical programme
SPSS 22 (IBM Corp, 2013).3. Results
A total of 1205 SUD patients were included: 196 (16.3%) with adult
ADHD (SUD + ADHD) and 1009 (83.7%) without adult ADHD (SUD-
ADHD) according to DSM-5. Table 1 shows the number of patients
from each country, the percentage of women and mean age. The per-
centage of women varied from 18% in the Netherlands to 34% in
Switzerland (Pearson chi square = 16.0, p= .013), and the mean age
varied from 36.8 years in France to 43.0 years in Hungary (F = 11.8,
p b .001). The primary substances of abuse in the sample were alcohol
(55%), followed by cannabis (11%), heroin (10%), cocaine (9%), amphet-
amine (6%), addictive medicines (e.g. opioids, benzodiazepines; 4%), il-
legal methadone (1%) and “other substances” (3%).Table 1
Countries of origin, number of patients, percentage women and mean age.
Country Number and percentage of total Percentage
females
Mean
age/SD
Sweden 165/13.7% 31% 42.6/11.6
Norway 175/14.5% 31% 37.6/10.8
Netherlands 125/10.4% 18% 40.7/10.1
Switzerland 152/12.6% 34% 42.5/10.8
France 154/12.8% 27% 36.8/10.7
Spain 220/18.3% 21% 37.1/9.7
Hungary 214/17.8% 25% 43.0/12.2
Total sample N= 1205 27% 40/11.23.1. Infant development
SUD+ADHD patients were signiﬁcantly slower in the development
of basic skills such as walking, talking, toilet training, as well as reading
(Table 2); (U=70753, p b 0.001, r=0.15). Similar results were obtain-
ed in the analysis with a 20% random selection of patients from SUD-
ADHD group (U= 6902, p= 0.008, r= 0.16).
3.2. Difﬁcult temperament
SUD + ADHD patients scored signiﬁcantly higher than SUD-ADHD
patients on temperamental difﬁculties (U = 35594, p b 0.001, r =
0.38) with similar results when using the 20% random selection of
SUD-ADHD patients (U = 6902, p b 0.001, r = 0.45). The
SUD+ADHDpatients reported strugglingmorewith difﬁculties related
to rage, anxiety, behavioural problems, clumsiness, eating and sleeping.
3.3. Problems at school
The SUD + ADHD group also had signiﬁcantly more school related
difﬁculties, both at primary school level (U = 42121, p b 0.001, r =
0.34) and at middle/high school level (U = 35643, p b 0.001, r =
0.34) with similar results when using the 20% random selection of
SUD-ADHD patients (primary school level: U = 9013, p b 0.001, r =
0.45; middle/high school level: U = 7899, p b 0.001, r = 0.45). The
SUD + ADHD group were substantially more likely to have struggled,
with reading and writing, had extra tuition, and experienced labelling
and expulsion from school than SUD-ADHD patients.
3.3.1. Gender
There were no signiﬁcant gender effects within the SUD + ADHD
group regarding infant development, difﬁcult temperament or school
problems. There was, however, a signiﬁcant effect within the SUD-
ADHD group for difﬁculties at elementary school, where boys had a
slightly higher score than girls (U= 80900, p b 0.001, r= 0.06).
3.4. Early diagnosis and professional help
Among the 196 SUD+ ADHD patients, 24 patients (12.2%) were di-
agnosed with ADHD as a child or adolescent, whereas the remaining
172 patients (87.8%) had never been diagnosed with ADHD before the
study. In the SUD-ADHD group, 50 patients (5.0%) had been diagnosed
with ADHD as a child. In the SUD+ADHD group, signiﬁcantlymore pa-
tients had seen a counsellor, psychologist or psychiatrist as a child than
in the SUD-ADHD group: SUD+ADHD47% vs. SUD-ADHD24% (Fischer
exact probability test p b .001). Among the reasons for seeking profes-
sional help, either through their parents or school, were behavioural
problems and acting out, difﬁculty concentrating, hyperactivity, depres-
sion, various forms of trauma and abuse, as well as truancy.
Seventeen percent of the SUD + ADHD group and 8% of the SUD-
ADHD group had taken medication for ADHD or for another mental
health problem as a child (Fisher exact probability test p b 0.001).
Among the medications that were mentioned were central stimulants
such as immediate release methylphenidate and OROS methylpheni-
date, but also other medications such as antidepressants, sleeping pills
and tranquilizers. Fifteen patients received ADHD medication as a
child: 8 from the SUD + ADHD group (4.0%) and 7 from the SUD-
ADHD group (0.7%), including 3 patients (0.3%) with childhood
ADHD-only (i.e. not adult ADHD).
3.5. Primary substance of abuse
In the SUD+ADHDgroup, 61% reported illicit drugs as their primary
substance, as compared to 41% in the SUD-ADHD group (Fisher exact
probability test p b 0.001). Table 3 shows the very different distribution
of the various primary substances being used in the two patient groups
Table 2
Problem area, mean scores and differences between SUD patients with and without adult attention deﬁcit hyperactivity disorder (ADHD).
SUD + ADHD
N= 196
SUD-ADHD
N= 1009
N M SD N M SD U-value p Value r
Infant development (0–4) 181 0.62 0.94 961 0.30 0.59 70753 b .000 0.15
Temperamental (0–13) 182 5.60 2.90 958 2.40 2.50 35594 b .000 0.38
Elementary school (0–15) 184 5.30 3.15 965 2.41 2.73 42121 b .000 0.34
Middle/high school (0–16) 168 5.70 2.84 898 2.95 2.72 35643 b .000 0.34
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(including amphetamine, methamphetamine and cocaine) and canna-
bis use disorder much more prevalent in the SUD + ADHD group than
in the SUD-ADHD group; stimulant use disorder 29.5% vs. 12.2%; canna-
bis use disorder 15.5% vs. 9.8%.
4. Discussion
The current study shows a substantial overrepresentation of all
childhood and adolescent problems in the SUD + ADHD group, espe-
cially more episodes with temperamental outburst, impulsiveness,
and impatience, along with poor school performance. The study also
clearly shows that surprisingly few SUD patients with ADHD (12%)
were diagnosed and treated as a child or adolescent for this disorder. Al-
most half of the SUD + ADHD patients and one quarter of the SUD-
ADHD patients had seen a professional for behavioural problems, im-
pulsivity and acting out, concentration problems, and a number of
other psychological symptoms. Only 4% of the SUD + ADHD patients
had been treated with a stimulant for childhood ADHD. Finally,
SUD + ADHD patients were more likely to have central stimulants or
cannabis as their primary substance of abuse, whereas alcohol use was
more likely to be the primary substance of abuse in SUD-ADHDpatients.
One should bear in mind that these are retrospective data and reli-
ability and validity may be limited by the patients' memory and ability
to recall childhood experiences and relevant information from their par-
ents and other close persons. The lack of collateral information from
childhood, home or school and the fact that the diagnosis was based
solely on information obtained from the patient, this may have led to
less accuracy because of poor self-knowledge or under-reporting.
4.1. Infant development and temperamental problems
The SUD + ADHD patients revealed more severe developmental
problems such as delay in walking, talking, toilet training and reading.
Furthermore, they had signiﬁcantly more temperamental difﬁculties
than the other group. This result reﬂects an increased burden in infancy
and early childhood regarding rage, anxiety, behavioural problems,
clumsiness, and eating problems. These problems have previously
been associated with hyperactivity-impulsivity (Chang, Lichtenstein, &
Larsson, 2012; Elkins, McGue, & Iacono, 2007). The difﬁculties are to a
large extent highly visible signs often associated with ADHD, but still
few of the patients were adequately identiﬁed and treated for their
ADHD.Table 3
Primary substance used for SUD patients with and without adult ADHD.
SUD + ADHD
N= 196
SUD-ADHD
N= 1009
N % N %
Alcohol 71 36.8 594 59.1
Opiates 23 11.9 103 10.2
Central stimulants 57 29.5 123 12.2
Cannabis 30 15.5 98 9.8
Other substances 12 6.2 87 8.7
Pearson's Chi-square = 53.4, p b 0.001.4.2. School experiences
The SUD + ADHD patients had signiﬁcantly poorer academic
achievements such as difﬁculties in reading, writing and arithmetic,
and many had repeated grades, learning disabilities, extra tuition, and
expulsion from school. Many of them were probably underachieving
at school. However, on the basis of this study it is impossible to say
whether their poor school performance was due to environmental or
biological/genetic factors, including ADHD. It probably reﬂects both
types of inﬂuence. Although ADHD patients show structural and func-
tional brain abnormalities in areas related to executive functions and
cognition (Cortese, 2012), psycho-educational interventions for ADHD
in school can contribute to improved academic performance and less
truancy and drop out from school (DuPaul & Eckert, 1997). The
school-based intervention literature suggests that particular attention
should be paid to the need for feasible, effective strategies that can be
used in general education settings with a variety of age groups with
ADHD (DuPaul, 2007).4.3. Diagnosis, medication and substance use
A minority of 12% of the SUD+ ADHD group had been identiﬁed as
having ADHD, but only 4% had received ADHDmedication during child-
hood or adolescence. The fact that so few had beenmedicated for ADHD
suggests the presence of scepticism towards medical treatment for
ADHD in children and adolescents.
Almost one third of the SUD+ADHDpatients in our study used cen-
tral stimulants as their primary drug, thus suggesting some sort of self-
medication that might have been avoided with proper, early treatment.
In a review of relevant literature on individuals with cocaine
dependence it was suggested that self-medication, and prescribed
psychostimulants may have beneﬁt in restoring dopaminergic function
(Mariani, Khantzian, & Levin, 2014). They suggest that psychostimulant
treatment of cocaine dependence is consistent with the self-medication
hypothesis and is deserving of further study.
Also cannabis was more prevalent in the ADHD group, which is in
line with ﬁndings in prior research (Charach Charach, Yeung, Climans,
& Lillie, 2011). It has been suggested that cannabismight reduce anxiety
(Vorspan, Mehtelli, Dupuy, Bloch, & Lépine, 2015) and restlessness, but
is unlikely to help with concentration (Bidwell, Henry, Willcutt,
Kinnear, & Ito, 2014). There might be many adults with undiagnosed
or untreated ADHD using cannabis who will not be identiﬁed because
their cannabis use does not cause them to present for treatment.
Apart from the self-medication hypotheses (using substances to de-
crease ADHD-symptoms and consequences), other possible causes have
been explored, such as the route via Oppositional Deﬁant Disorder/Con-
duct Disorder and Antisocial Personality Disorder (Flory & Lynam, 2003)
and common underlying genetic/neurobiological factors (Arcos-Burgos,
Vélez, Solomon, & Muenke, 2012; Ivanov, Schultz, London, & Newcorn,
2008). Regardless of the mechanism underlying the linkage between
ADHD and SUD, early treatment of ADHD might have a protective inﬂu-
ence on the development of SUD. If so, early detection of ADHD is of
major importance for the prevention of SUD development in children
and adolescents with this disorder. The factors presented in this paper
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comorbid SUD and, thus, might help in this early detection.
It has been argued that pharmacological treatment of ADHD with
stimulant medication may lower the threshold for future abuse, al-
though to date the evidence regarding the effect of stimulant treatment
on the risk of later substance use disorders is mixed. Whilst a recent
meta-analytic review concluded that stimulant treatment does not af-
fect the risk for substance use disorders (Humphreys, Eng, & Lee,
2013), subsequently published studies suggest otherwise. A meta-
analysis on stimulant treatment of ADHD and its effect on the develop-
ment of nicotine dependence (Schoenfelder, Faraone, & Kollins, 2014)
concluded that there is a signiﬁcant association between stimulant
treatment of ADHD patients and lower smoking rates in these patients.
Also, a recent European study showed that stimulant treatment appears
to lower the risk of developing substance use disorders in adolescents
with ADHD, especially if the treatment is started at a young age
(Groenman et al., 2013).
4.4. Conclusions and clinical implications
Based on present knowledge, early diagnosis of ADHD, proper med-
ical and psychological treatment, as well as psycho-education, is of crit-
ical importance. Treatment and educational support for youngsterswith
ADHD is available and may make a major difference in the lives of this
group. It may also prevent the development of substance use disorders
in late adolescence and adulthood.
Many of the patients have been in contact with health and school
services, in conjunction with ADHD associated symptoms, without hav-
ing been diagnosed with ADHD. Behavioural symptoms such as more
temperamental outbursts, impulsiveness, hyperactivity and impatience,
alongwith poor school performance, seem to be associated with subse-
quent development of a substance use disorder in this group of children
with ADHD. It is therefore important that children with such symptoms
receive an adequate follow-up and treatment as early as possible so that
one can potentially prevent later drug addiction. In order to achieve that
goal, more attention and expertise in educational and health agencies in
relation to the detection and treatment of ADHD are needed.
The SUD and ADHD patients in this study were offered further
assistance. Some have been in individual or group therapy for ADHD
with a focus on improving the structure and planning of everyday life,
others have received medical attention, and some have received both.
It is beyond this article's focus, but it would be interesting to follow
them up further. A positive effect of drug therapy in relation to this
dual diagnosis group of adults has not been convincingly documented
in the research literature, and the need for research on multimodal
treatment including both medical (e.g. Konstenius et al., 2014) and
psychological approaches (e.g. van Emmerik-van Oortmerssen et al.,
2013) is great.
Role of funding source
The ICASA Foundation (www.adhdandsubstanceabuse.org) devel-
oped the IASP study, and arranged with its participating institutes that
each of these institutes would seek funding for their regional process
and data sampling efforts. The ICASA Network sought funding for the
central organization costs. These central costs included:
- Organizing meetings for the network;
- Site visits for training andmonitoring (the last author (VdG G) visit-
ed all of the institutes at least once, the European institutes were
visited twice);
- Building a data base ﬁt for remote data storage at the University of
Amsterdam;
- Obtaining the right for use of the CAADID interview;
- Translating the instruments in the necessary languages;- Cleaning the data;
- Analysing the study results and coordinating publishing;
In the period of development of the study (2005–2010) the ICASA
network received unrestricted grants from the following pharmaceuti-
cal companies: Janssen Cilag, Eli Lilly and Company, Shire. Since the
ICASA Network is a formal foundation (September 2010) it operates in-
dependent from pharmaceutical funding. Since then funding was ob-
tained via the following sources:
- Participating institutes;
- The Noaber Foundation;
- The Waterloo Foundation;
- The Augeo Foundation.
The funding companies, institutes and foundations did not have and
will not have inﬂuence on any aspect of the study, including research
questions, data sampling, data management, data analyses and publish-
ing results.
The local institutes report the following funding sources: The
Netherlands, Amsterdam: no external fundingwas obtained. The partic-
ipating institute, Arkin, paid for the costs involved, and used funding
from Fonds NutsOhra for this project.
Norway, Bergen Clinics Foundation: Main external funding has been
the Regional research council for addiction in West Norway (Regionalt
kompetansesenter for rusmiddelforskning i Helse Vest (KORFOR)),
funding a 50% position. The remaining resources, with staff and infra-
structure, have been from the Bergen Clinics Foundation.
Norway, Fredrikstad: The IASP was funded by the hospital, Syke-
huset Østfold HF, not with money, but with 50% of the salary of the
participants, then by two sources outside the hospital: The Regional
Center of Dual Diagnosis and the Social and Health directory.
Sweden, Stockholm: The study was funded by the Stockholm Center
for Dependency Disorders.
Belgium: Funding of the IASP-project in Belgium: private funding.
France, Bordeaux: Research Grant PHRC (2006–2012) from the French
Ministry of Health and the French Government Addiction Agency
MILDT grant 2010 toM. Auriacombe and by a French National Research
Agency PRA-CNRS-CHU-Bordeaux award(2008–2010) to M. Fatséas.
Spain, Barcelona: Financial support was received from PlanNacional
sobre Drogas, Ministerio de Sanidad y Política Social (PND0080/2011),
the Agència de Salut Pública de Barcelona and the Departament de
Salut. Government of Catalonia, Spain.
Switzerland, Bern/Zürich: The IASP in Switzerland was funded by
the Swiss Foundation of Alcohol Research (Grant # 209).
Hungary, Budapest: There was no direct funding, but the following
grant was used: The European Union and the European Social Fund
have provided ﬁnancial support to the project under the grant agree-
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